Curated News
By: NewsRamp Editorial Staff
August 13, 2024
Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions
Discuss on Reddit
Discuss on SubstackTLDR
- Investors can gain insight into Clene's promising drug candidate CNM-Au8, which targets neurodegenerative diseases.
- CNM-Au8 enhances cellular energy production and utilization to improve neuronal health in neurodegenerative diseases.
- Clene's research and drug development offer hope for treating neurodegenerative diseases, ultimately improving the lives of patients.
- Clene's lead drug candidate, CNM-Au8, is a promising advancement in the treatment of neurodegenerative diseases.
Impact - Why it Matters
This news matters as it highlights the significant strides made by Clene Inc. in developing CNM-Au8 as a potential treatment for neurodegenerative diseases, which have limited current treatment options. The company's research and findings presented at the Emerging Growth Conference 73 demonstrate promising developments in the ALS treatment market, which is poised for growth due to an aging population.
Summary
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). In the recent Emerging Growth Conference 73 on July 17-18, 2024, CEO Rob Etherington and CFO Morgan Brown presented new findings and information about the company and its lead drug candidate, pertinent to current and potential investors.
Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases. The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions
